Table 4.
Clinical research of GSIs in the treatment of leukemia
| Test | Preclinical study | Phase I |
|---|---|---|
| Drug |
RO4929097 |
MK-0752 |
| Methods |
8 mice (leukemia models) were used in each control or treatment group. |
Six adult and two pediatric patients with leukemia (seven with T-ALL and one with AML) received MK-0752 |
| Percentages of human CD45+ cells were determined | ||
| Results |
No significance in event-free survival [53] |
Limited antitumor activity and major gastrointestinal toxicity |
| Comments | [75] | [76] |